Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma
Status:
Withdrawn
Trial end date:
2021-06-11
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well leflunomide works in treating patients with high-risk
smoldering multiple myeloma. Leflunomide may stop the growth of cancer cells by blocking some
of the enzymes needed for cell growth.